#ICCBH2026
LightNews LightNews
nejm.org
In a phase 3, randomized trial involving children with achondroplasia (3 to 17 years of age), once-daily oral infigratinib for 1 year significantly increased the annualized height velocity as compared with placebo. Full PROPEL 3 trial results: https://nej.md/4w8vTJc

#ICCBH2026
A graph from the Original Article "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia." The trial name, PROPEL 3, is in parentheses next to the title. The graph shows mean change in annualized height velocity from baseline for the Infigratinib and placebo groups. The trial results are being presented at the International Conference on Children's Bone Health. The logo of The New England Journal of Medicine is at the bottom.
June 28, 2026 at 8:05 PM